Primary Hyperlipidemia Or Mixed Dyslipidemia Therapeutics
1. Livalo patent expiration
Treatment: Adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with
LIVALO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753675 | KOWA CO | Quinoline analogs of mevalonolactone and derivatives thereof |
May, 2015
(10 years ago) | |
| US6465477 | KOWA CO | Stable pharmaceutical composition |
Dec, 2016
(9 years ago) | |
|
US5856336 (Pediatric) | KOWA CO | Quinoline type mevalonolactones |
Jun, 2021
(4 years ago) | |
| US5856336 | KOWA CO | Quinoline type mevalonolactones |
Jan, 2021
(5 years ago) | |
| US5854259 | KOWA CO | Quinoline type mevalonolactones |
Dec, 2015
(10 years ago) | |
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(1 year, 10 months ago) | |
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(1 year, 11 months ago) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(1 year, 4 months ago) | |
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Dosage: TABLET
How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage
LIVALO family patents
